Select Medical Holdings Corp
10 nominees · 3 ballot items.
Three proposals: (1) Merger Proposal to adopt the Agreement and Plan of Merger and approve related transactions; (2) Compensation Proposal — non-binding, advisory vote to approve golden parachute/merger-related compensation to named executive officers; (3) Adjournment Proposal to adjourn the Special Meeting to solicit additional proxies if needed.
Follow how the vote landed and what changed on Select Medical Holdings Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
On the ballot3
- 1
The Merger Proposal
ManagementBoard: FORAdopt the Agreement and Plan of Merger dated March 2, 2026 and approve the transactions contemplated by the Merger Agreement, including the merger where the company becomes a wholly-owned subsidiary of Parent and holders will receive $16.50 per share in cash (subject to exceptions and appraisal rights).
More detail
The Merger Proposal asks shareholders to approve an Agreement and Plan of Merger under which Parent will acquire all outstanding Company Shares for $16.50 per share in cash, subject to specified exceptions (including rollover shares) and applicable tax withholdings. Management and the Special Committee negotiated the transaction following a strategic review; Goldman Sachs delivered a fairness opinion that the price is fair from a financial point of view to unaffiliated shareholders. Approval requires both a majority of all outstanding shares entitled to vote and a majority excluding Parent-affiliated stockholders; broker non-votes and abstentions count as against the Merger. The board recommends approval citing the Special Committee’s process, independent advisors, premium to unaffected trading price, and limited realistic alternative bidders. The Merger Agreement includes customary covenants, non-solicitation provisions with fiduciary out, termination fees (including a Company Termination Fee of $66,504,813 and a Parent Termination Fee), appraisal rights under Delaware law for dissenting shareholders, and conditions such as regulatory clearances and financing commitments. The vote is a condition to closing; if not approved, the company remains public and shareholders retain ongoing exposure. The recommendation reflects the board’s view that the price and transaction terms balance execution certainty with protections for unaffiliated shareholders, while acknowledging risks including lost future upside, regulatory approval risk, and potential conflicts from insiders and rollover holders.
- 2
The Compensation Proposal
ManagementBoard: FORNon-binding, advisory approval of the merger-related compensation (golden parachute) that will or may become payable to the Company’s named executive officers as disclosed in the proxy statement.
- 3
The Adjournment Proposal
ManagementBoard: FORApprove adjournment of the Special Meeting from time to time, to a later date(s) to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the Special Meeting.
More detail
The Adjournment Proposal seeks shareholder approval to adjourn the Special Meeting to solicit additional proxies if there are insufficient votes to approve the Merger Agreement, or if a quorum is absent, within specified limitations. Management requests this authority to allow more time to persuade shareholders and to obtain the Requisite Stockholder Approvals; the proposal sets caps on aggregate adjournment time and parental consent for certain adjournments. The board recommends approval to preserve flexibility to secure approval of the Merger, acknowledging the potential for strategic use of adjournment to change voting outcomes. A vote for the Adjournment Proposal will not alter the substance of the Merger Agreement but could materially affect the timing and ultimate outcome of the shareholder decision by permitting further solicitation and potentially changing vote tallies.
Nominees on the ballot10
Top institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | 9.5% | 11,729,407 | $191M |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5.4% | 6,723,557 | $110M |
| 3 | DIMENSIONAL FUND ADVISORS LP | 4.2% | 5,261,680 | $86M |
| 4 | FIL Ltd | 4.0% | 4,960,732 | $81M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 4,819,685 | $79M |
| 6 | STATE STREET CORP | 3.5% | 4,319,877 | $70M |
| 7 | GLAZER CAPITAL, LLC | 3.3% | 4,079,780 | $66M |
| 8 | BlackRock, Inc. | 3.0% | 3,765,918 | $61M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 2,275,539 | $37M |
| 10 | HSBC HOLDINGS PLC | 1.8% | 2,233,769 | $36M |
Other Healthcare sector meetings6
Upcoming shareholder meetings at Select Medical Holdings Corp’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Frequently asked questions
- When is the Select Medical Holdings Corp 2026 special meeting?
- Select Medical Holdings Corp (SEM) holds its 2026 special shareholder meeting on Friday, June 26, 2026.
- What is the record date for the Select Medical Holdings Corp 2026 meeting?
- The record date for the Select Medical Holdings Corp 2026 meeting is Monday, May 11, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Select Medical Holdings Corp's 2026 meeting?
- The board is presenting 10 director nominees at the Select Medical Holdings Corp 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Select Medical Holdings Corp 2026 meeting?
- Shareholders will vote on 3 proposals at the Select Medical Holdings Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.